FL-JABIL
3.2.2020 15:02:07 CET | Business Wire | Press release
Jabil Inc. (NYSE: JBL) today announced the consolidation of its entire healthcare organization under Jabil Healthcare, led by Steve Borges, CEO and EVP. Jabil Healthcare combines, under a single umbrella, Nypro with its Orthopedics, Spine, Trauma and associated medical instruments operations. With more than 35 global sites and nearly 20,000 employees serving the leading brands in healthcare, this powerful combination makes Jabil the largest healthcare manufacturing solutions provider.
Jabil Healthcare serves five key sectors in the healthcare market: medical devices, orthopedics, diagnostics, pharmaceutical delivery systems, and consumer health. In each arena, demand for value-based care solutions is forcing significant changes in the evolution of healthcare products and services and driving digital health innovations. Taking center stage are Internet of Things (IoT) and digital health platform innovations enabled by connectivity, sensors and miniaturization.
“By harnessing the power of the Jabil and Nypro teams, we are in the unique position to accelerate technology advancements and augment the value we bring to our customers, their patients and the healthcare industry,” said Borges. “With the rise of digital health and additive manufacturing, the time is right to unite our diverse capabilities and domain expertise under one strong brand.”
Jabil Healthcare unifies the company’s medical industry know-how with deep cross-sector experience in injection molding, electronics, sensor integration, and additive manufacturing to help healthcare brands accelerate and scale technology advancements. This integrated line of capabilities across Jabil is brought to bear for its base of healthcare customers, from emerging startups to global enterprises.
The support of women’s technology company, Elvie, is just one example. “We're in the connected health space, which is actually quite a new area. We needed expertise in everything from hardware to firmware to software,” said Tania Boler, CEO of Elvie, in a Jabil Healthcare case study released today. “When we tried to select the best in class manufacturing partner for us, to be honest, Jabil was the no-brainer solution because they have had so much experience across so many different partners in so many different product categories.”
“With more than 50 years of expertise, Jabil Healthcare is well versed in integrating components and subsystems into pharmaceutical, orthopedic, diagnostic, medical and consumer healthcare devices,” Borges said. “As a united team with a clear mission, we are powerfully positioned to help our customers deliver high-quality, innovative products and services that improve patient outcomes.”
About Jabil
Jabil (NYSE: JBL) is a manufacturing solutions provider that delivers comprehensive design, manufacturing, supply chain and product management services. Leveraging the power of over 200,000 people across 100 sites strategically located around the world, Jabil simplifies complexity and delivers value in a broad range of industries, enabling innovation, growth and customer success. For more information, visit jabil.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005387/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian Expands Agent Trust Partner Ecosystem with Akamai to Advance Trusted AI Driven Commerce15.5.2026 15:00:00 CEST | Press release
Collaboration strengthens secure, scalable agentic commerce and supports emerging Know Your Agent standards Experian today announced that Akamai Technologies has joined its growing partner ecosystem, designed to further advance secure, trusted AI driven commerce through the Experian Agent Trust™ framework, alongside partner Skyfire supporting emerging payment innovation. As AI agents begin to search, decide, and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer directly initiated by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust is designed to address this challenge by establishing identity, accountability, and trust in agent driven interactions. “Trust, security, and performance must scale alongside the growing role of AI agents in digital commerce,” said Kathleen Peters,
The LYCRA Company and Dukane Advance Ultrasonic Bonding for Nonwovens at INDEX™ 2615.5.2026 14:00:00 CEST | Press release
LYCRA FUSION™ Fiber for Personal Care Applications Debuts The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the personal care industry, and Dukane, a manufacturer of ultrasonic bonding technologies for the hygiene and nonwovens market, are showcasing their latest co-developed advances in ultrasonic bonding at INDEX™ 26, taking place in Geneva, Switzerland, from May 19–22. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515514441/en/ Join The LYCRA Company and Dukane at INDEX™ 26 in Geneva, as they showcase their latest advances in ultrasonic bonding for nonwovens, including new LYCRA FUSION™ fiber for personal care that delivers superior snapback. Since 2014, both companies have collaborated to advance ultrasonic bonding solutions that help diaper manufacturers improve product softness, fit, and performance while reducing energy consumption, material waste, and maintenance costs. Ultrason
Vecima to Highlight Next-Generation 50G-PON, DOCSIS® 4.0 vCMTS, AI & Automation, and Monetizable Streaming at ANGA COM 202615.5.2026 13:45:00 CEST | Press release
Vecima Networks Inc. (TSX: VCM) will highlight its leadership in next-generation broadband at ANGA COM 2026, showcasing AI-powered network operations, cloud-native DOCSIS® 4.0 access, and scalable fiber solutions. Anchored by the Entra® vCMTS platform, Automation, and All-PON™ innovations, Vecima is enabling operators to automate operations, improve reliability, and accelerate the evolution to converged cable and fiber networks. Delivering on Next-Generation PON With Entra All-PON™, Vecima is enabling future-ready fiber networks with a straightforward migration path from today’s 10G technologies to 50G-PON, ensuring long-term scalability and investment protection. The new Entra EPS1650 All-PON Shelf supports 50G-PON, XGS-PON, 10G-EPON, GPON, and EPON services. As a follow-on to Vecima's industry-first demonstration of a single port supporting 50G ITU PON and 10G-EPON in a Remote OLT, the EPS1650 brings that same single-port investment-protection path to GPON and XGS-PON operators in a
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom